Otsuka Pharmaceutical Co. Ltd. has further expanded its digital therapeutic portfolio for psychiatric indications through the 1 April US Food and Drug Administration (FDA) approval of digital therapeutic Rejoyn.
Otsuka Progresses Digital Push With US Approval Of MDD App
First Such Adjunctive Therapy
Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.
